Stay updated with breaking news from Mini Oral Presentation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Sugemalimab is the world's first PD-L1 monoclonal antibody that when administered along with chemotherapy improved overall survival of first-line metastatic...
Sugemalimab is the world's first PD-L1 monoclonal antibody that when administered along with chemotherapy improved overall survival of first-line metastatic...
CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients - read this article along with other careers information, tips and advice on BioSpace
SUZHOU, China, Dec. 21, 2021 /PRNewswire/ -- CStone Pharmaceuticals (the "Company" or "CStone") is pleased to announce that the National Medical Products Administration ("NMPA") of China has
Press release content from PR Newswire. The AP news staff was not involved in its creation.